Cargando…

Adverse effects of oral antiviral therapy in chronic hepatitis B

Oral nucleoside/nucleotide analogues (NAs) are currently the backbone of chronic hepatitis B (CHB) infection treatment. They are generally well-tolerated by patients and safe to use. To date, a significant number of patients have been treated with NAs. Safety data has accumulated over the years. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kayaaslan, Bircan, Guner, Rahmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316843/ https://www.ncbi.nlm.nih.gov/pubmed/28261380 http://dx.doi.org/10.4254/wjh.v9.i5.227

Ejemplares similares

COVID-19 and the liver: A brief and core review
por: Kayaaslan, Bircan, et al.
Publicado: (2021)

Comparison of Antibiotic Regimens in Intra-abdominal Infections
por: Hasanoglu, Imran, et al.
Publicado: (2017)

Investigation of the relation between risk assessment of exposure and nosocomial SARS-CoV-2 transmission in healthcare workers: a prospective single-centre study
por: Kaya Kalem, Ayse, et al.
Publicado: (2022)

Effect of 2 Different High-Dose Methylprednisolone Treatments on Clinical Outcomes in Severe COVID-19 Patients
por: Eser, Fatma, et al.
Publicado: (2023)

Reply to letter to the editor: “Interleukin-6 level, right ventricular systolic dysfunction, and coronavirus disease 2019”
por: Erdoğan, Mehmet, et al.
Publicado: (2022)

Investigation of SARS-CoV-2 using RT-PCR in vaginal swab samples of female patients with a diagnosis of severe COVID-19
por: Erdem, Deniz, et al.
Publicado: (2023)

Do Lifestyle Changes of Renal Transplant Recipients During the Pandemic Reduce the Risk of Coronavirus Disease 2019?
por: Hasanoglu, Imran, et al.
Publicado: (2020)

COVID-19 patients with altered steroid hormone levels are more likely to have higher disease severity
por: Sezer, Sevilay, et al.
Publicado: (2022)

A useful and sensitive marker in the prediction of COVID-19 and disease severity: Thiol
por: Kalem, Ayse Kaya, et al.
Publicado: (2021)

Current Antiviral Therapy for Chronic Hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2004)

Antiviral therapy for chronic hepatitis B in China
por: Zheng, Xin, et al.
Publicado: (2014)

Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg
por: Hasanoglu, Imran, et al.
Publicado: (2020)

Current Trend in Antiviral Therapy for Chronic Hepatitis B
por: Chien, Rong-Nan, et al.
Publicado: (2022)

Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B
por: Xu, Kerui, et al.
Publicado: (2018)

Tenofovir disoproxil fumarate may not cause renal and bone toxicity in chronic hepatitis B patients: a retrospective cross-sectional study
por: GÜNER, Rahmet, et al.
Publicado: (2019)

Adherence to Nucleoside/Nucleotide Analogue Treatment in Patients with Chronic Hepatitis B
por: Tütüncü, Emin Ediz, et al.
Publicado: (2017)

Management of Hepatitis C Antiviral Therapy Adverse Effects
por: Sung, Hubert, et al.
Publicado: (2010)

Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients
por: Okumuş, Nurullah, et al.
Publicado: (2021)

Management of Antiviral Resistance in Chronic Hepatitis B
por: Lim, Young-Suk
Publicado: (2017)

Advances in new antivirals for chronic hepatitis B
por: Tang, Yanhua, et al.
Publicado: (2022)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Crushing the curve, the role of national and international institutions and policy makers in COVID-19 pandemic
por: KOÇAK TUFAN, Zeliha, et al.
Publicado: (2020)

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
por: Varbobitis, Ioannis, et al.
Publicado: (2016)

Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation
por: Lin, Su, et al.
Publicado: (2017)

Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
por: Lam, Yuk-Fai, et al.
Publicado: (2011)

Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Recent Advances in Antiviral Therapy for Chronic Hepatitis C
por: Tamori, Akihiro, et al.
Publicado: (2016)

Antimicrobial stewardship in the intensive care unit
por: Ture, Zeynep, et al.
Publicado: (2022)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections(†)
por: De Clercq, Erik, et al.
Publicado: (2010)

The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
por: Tillmann, Hans Ludger
Publicado: (2008)

Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States
por: Saab, Sammy, et al.
Publicado: (2016)

Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection
por: Chae, Hee Bok, et al.
Publicado: (2007)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
por: Bayhan, Gulsum Iclal, et al.
Publicado: (2022)

Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy
por: Şahin, Ahmet, et al.
Publicado: (2018)

Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy
por: Moehlen, Martin, et al.
Publicado: (2013)

COVID-19 and Sepsis
por: KOÇAK TUFAN, Zeliha, et al.
Publicado: (2021)

Access to antiviral therapy for chronic hepatitis B during COVID-19
por: Bertolli¹, Marilia Rocha, et al.
Publicado: (2022)

An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_og8q37m1lknaics3l6on2ef0i0